Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
India Business grew by 11.9% YoY to Rs. 1196.2 crore
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
Morepen Labs successfully raised Rs. 200 Crore through QIP
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
Subscribe To Our Newsletter & Stay Updated
